HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

495.218

-4.773-0.95%

Number of Gainers:6

Number of Losers:24

Number of Flat:4

PE:- -

High:501.988

Open:500.023

Low:490.944

Close:499.991

Loading ...

Suzhou Basecare Medical Corp. Ltd. Conducted Annual and Class Shareholders Meetings

Zai Lab Ltd. Announces New Compensation Plan with Grant of Share Options and Restricted Share Units under 2024 Equity Incentive Plan

Akeso's Pd-1/Ctla-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab

THOMSON REUTERS

Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer

Akeso - Nmpa Approved Snda for Cadonilimab as First-Line Treatment for Cervical Cancer

THOMSON REUTERS

Zai Lab Ltd. CFO Yajing Chen Reports Disposal of Common Shares

HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX Announcing Repurchase of 200,000 Shares at HKD 8.7394 Each

Zhaoke Ophthalmology Ltd. Secures FDA Clearance for IND Application of CsA Ophthalmic Gel for Dry Eye Disease Treatment

Zhaoke Ophthalmology Ltd - FDA Clearance of Ind Application for Csa Ophthalmic Gel

THOMSON REUTERS

BUZZ-Sagimet soars as oral acne drug aces late-stage trial in China

Sagimet Biosciences Shares Jump 52% Premarket After Oral Acne Drug With Partner Ascletis Met the Main Goals in a Late-Stage Trial

THOMSON REUTERS

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne

Acotec Scientific Holdings Ltd. Receives PRC National Medical Products Administration Approval for AcoArt Verbena® Paclitaxel-Coated Balloon Catheter

Acotec Scientific - Approval for Vertebral Artery Paclitaxel-Coated- Balloon Dilatation Catheter Acoart Verbena by Nmpa

THOMSON REUTERS

Ascletis Pharma Announces Successful Phase III Trial of Denifanstat, a Groundbreaking Oral FASN Inhibitor for Acne Treatment

Ascletis Announces Phase Iii Trial of Denifanstat (Asc40), a First-in-Class, Once-Daily Oral Fasn Inhibitor for Acne, Meets All Endpoints

THOMSON REUTERS

Ascletis Pharma Inc - Announces Phase Iii Trial of Denifanstat Meets All Endpoints

THOMSON REUTERS

HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX Announcing Repurchase of 100,000 Shares at HKD 9.0667 Each

Brii Biosciences Ltd. Conducted Annual General Meeting

JW Cayman Therapeutics Co. Ltd. Held Extraordinary General Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":495.218,"timestamp":1749189450773,"preClose":499.99072,"halted":0,"volume":79861256,"delay":0,"changeRate":-0.009546,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-4.772736,"latestTime":"06-06 13:57:32","open":500.0226,"high":501.98834,"low":490.94357,"amount":1432654688,"amplitude":0.02209,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1749197400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":4.144536,"peRate":-25.524806,"turnoverRate":0.003029,"increases":6,"decrements":24,"flats":3,"marketCap":289636635584,"floatMarketCap":265452345136},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":501.98834,"amplitude":0.02209,"preClose":499.99072,"low":490.94357,"pbRate":"4.144536","latestPrice":495.218,"volume":79861256,"delay":0,"open":500.0226,"prevYearClose":331.1933,"prevWeekClose":491.683,"prevMonthClose":491.683,"prevQuarterClose":455.082,"fiveDayClose":491.683,"twentyDayClose":458.671,"sixtyDayClose":437.197,"secType":"PLATE","market":"HK","turnoverRate":0.003029,"peRate":-25.524806,"marketCap":289636635584,"floatMarketCap":265452345136,"timestamp":1749189450773,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":24,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541205220","title":"Suzhou Basecare Medical Corp. Ltd. Conducted Annual and Class Shareholders Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2541205220","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541205220?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:10","pubTimestamp":1749125403,"startTime":"0","endTime":"0","summary":"Suzhou Basecare Medical Corp. Ltd. held its 2024 Annual General Meeting, the 2025 First Class Meeting for Holders of Domestic Shares and Unlisted Foreign Shares, and the 2025 First Class Meeting for Holders of H Shares on June 5, 2025. All proposals at the AGM and the Domestic Shareholders and Unlisted Foreign Shareholders Class Meeting were approved by the shareholders. However, one resolution at the H Shareholders Class Meeting was not passed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Basecare Medical Corp. Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL71q5FP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02170","BK1222","BK1597"],"gpt_icon":0},{"id":"2541027775","title":"Zai Lab Ltd. Announces New Compensation Plan with Grant of Share Options and Restricted Share Units under 2024 Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2541027775","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541027775?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:00","pubTimestamp":1749124836,"startTime":"0","endTime":"0","summary":"Zai Lab Ltd. Announces New Compensation Plan with Grant of Share Options and Restricted Share Units under 2024 Equity Incentive Plan. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL19MmkK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU2488822045.USD","BK1588","BK1161","09688"],"gpt_icon":0},{"id":"2541981015","title":"Akeso's Pd-1/Ctla-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2541981015","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541981015?lang=en_us&edition=fundamental","pubTime":"2025-06-05 09:36","pubTimestamp":1749087418,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nTUACG1H0G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B5MMRT66.SGD","LU2488822045.USD","LU1794554557.SGD","LU0417516571.SGD","IE00B543WZ88.USD","09926","IE00BPRC5H50.USD","LU1720050803.USD","BK1574","BK1161","LU0348784397.USD","LU0348783233.USD"],"gpt_icon":0},{"id":"2541904690","title":"Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2541904690","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541904690?lang=en_us&edition=fundamental","pubTime":"2025-06-05 08:19","pubTimestamp":1749082781,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced a significant regulatory milestone, as the National Medical Products Administration  of China has approved the supplemental New Drug Application  for cadonilimab . This approval allows the use of cadonilimab in combination with platinum-based chemotherapy, with or without bevacizumab, as a first-line treatment for persistent, recurrent, or metastatic cervical cancer. This marks the third approved indication for cadonilimab and addresses the critical unmet needs for immune-based therapies for cervical cancer patients in China. The approval is based on the successful results of the COMPASSION-16/AK104-303 study, which demonstrated significant improvements in progression-free survival and overall survival.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL3qpqQ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","IE00B5MMRT66.SGD","BK1161","09926","LU0417516571.SGD","LU0348783233.USD","LU0348784397.USD","IE00BPRC5H50.USD","LU2488822045.USD","LU1720050803.USD","LU1794554557.SGD","BK1574"],"gpt_icon":1},{"id":"2541090985","title":"Akeso -  Nmpa Approved Snda for Cadonilimab  as First-Line Treatment for Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2541090985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541090985?lang=en_us&edition=fundamental","pubTime":"2025-06-05 08:17","pubTimestamp":1749082675,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S70DJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B543WZ88.USD","LU0417516571.SGD","LU2488822045.USD","BK1574","09926","IE00BPRC5H50.USD","LU0348784397.USD","LU1720050803.USD","IE00B5MMRT66.SGD","BK1161","LU1794554557.SGD","LU0348783233.USD"],"gpt_icon":0},{"id":"2541999010","title":"Zai Lab Ltd. CFO Yajing Chen Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2541999010","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541999010?lang=en_us&edition=fundamental","pubTime":"2025-06-05 04:35","pubTimestamp":1749069312,"startTime":"0","endTime":"0","summary":"Chen Yajing, the Chief Financial Officer of Zai Lab Ltd., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL1hJkT9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Zai Lab Ltd. CFO Yajing Chen Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2488822045.USD","09688","BK1588","BK1574"],"gpt_icon":0},{"id":"2540069128","title":"HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX Announcing Repurchase of 200,000 Shares at HKD 8.7394 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2540069128","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540069128?lang=en_us&edition=fundamental","pubTime":"2025-06-04 21:34","pubTimestamp":1749044046,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange, revealing the repurchase of 200,000 shares to be held as treasury shares. The shares were repurchased at a total price of HKD 1,747,870, with an average price of HKD 8.7394 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL2SgVz5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1583","BK1161"],"gpt_icon":0},{"id":"2540705409","title":"Zhaoke Ophthalmology Ltd. Secures FDA Clearance for IND Application of CsA Ophthalmic Gel for Dry Eye Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540705409","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540705409?lang=en_us&edition=fundamental","pubTime":"2025-06-04 18:08","pubTimestamp":1749031684,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology Ltd. has announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for its core product, Cyclosporine  Ophthalmic Gel. This gel is being developed for the treatment of moderate-to-severe dry eye disease and will advance to a Phase III, multicenter, randomized, double-masked, active-controlled study. The FDA's clearance allows Zhaoke to incorporate data from its completed pivotal Phase III clinical trial  and ongoing Phase III trial in China into its U.S. development plan. This regulatory milestone marks a significant step forward for Zhaoke in potentially improving patient compliance and quality of life with its innovative once-daily application gel.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL9fqH1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","06622","BK1587","BK1191","BK1574"],"gpt_icon":0},{"id":"2540405408","title":"Zhaoke Ophthalmology Ltd - FDA Clearance of Ind Application for Csa Ophthalmic Gel","url":"https://stock-news.laohu8.com/highlight/detail?id=2540405408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540405408?lang=en_us&edition=fundamental","pubTime":"2025-06-04 18:06","pubTimestamp":1749031586,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70EH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1191","BK1587","06622","BK1574"],"gpt_icon":0},{"id":"2540055112","title":"BUZZ-Sagimet soars as oral acne drug aces late-stage trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2540055112","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540055112?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:27","pubTimestamp":1749029233,"startTime":"0","endTime":"0","summary":"BUZZ-Sagimet soars as oral acne drug aces late-stage trial in China** Shares of drug developer Sagimet Biosciences SGMT.O rise 52% to $5.53 premarket** SGMT says its oral acne drug, denifanstat, met the main goals in a late-stage trial conducted by its Chinese partner Ascletis 1672.HK** Denifanstat showed 33.2% treatment success rate versus 14.6% for placebo** Denifanstat works by inhibiting the production of sebum, a key contributor to acne, through a novel mechanism of action, co says** The drug reduced total acne lesions by 57.4% compared to 35.4% with placebo** Ascletis plans to submit denifanstat for approval to Chinese regulators** As of last close, stock down 19.3% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nL3N3S70LM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1515","BK1161","BK1574","01672","SGMT"],"gpt_icon":0},{"id":"2540055977","title":"Sagimet Biosciences Shares Jump 52% Premarket After Oral Acne Drug With Partner Ascletis Met the Main Goals in a Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540055977","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540055977?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:15","pubTimestamp":1749028555,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK1515","BK1161","BK4139","BK1574","01672"],"gpt_icon":0},{"id":"2540053848","title":"Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat in Treating Moderate-to-Severe Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2540053848","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540053848?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:00","pubTimestamp":1749027616,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, announced the positive results of a Phase 3 clinical trial conducted by its license partner, Ascletis Bioscience Co. Ltd. in China, for the treatment of moderate to severe acne vulgaris. The trial evaluated the oral small molecule fatty acid synthase  inhibitor, denifanstat, which met all primary and secondary endpoints versus a placebo and was well tolerated by participants. This development marks an advancement in acne treatment, introducing a novel mechanism of action through FASN inhibition. Additionally, Sagimet has initiated a Phase 1 clinical trial in the United States for a second FASN inhibitor, TVB-3567, targeting acne treatment. The positive outcomes from the trial underscore the potential of FASN inhibition as a therapeutic approach for acne.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL9NgkYx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4139","BK1515","IE00BKPKM429.USD","BK1161","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4112","LU2210150020.SGD","01672","LU2095319765.USD","BK4585","LU2210149790.SGD","BK1574","SGMT","BK4588","NDAQ"],"gpt_icon":0},{"id":"2540058386","title":"Acotec Scientific Holdings Ltd. Receives PRC National Medical Products Administration Approval for AcoArt Verbena® Paclitaxel-Coated Balloon Catheter","url":"https://stock-news.laohu8.com/highlight/detail?id=2540058386","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540058386?lang=en_us&edition=fundamental","pubTime":"2025-06-04 16:44","pubTimestamp":1749026695,"startTime":"0","endTime":"0","summary":"Acotec Scientific Holdings Ltd. Receives PRC National Medical Products Administration Approval for AcoArt Verbena Paclitaxel-Coated Balloon Catheter. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acotec Scientific Holdings Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL4NlyGT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSX","LU0077335932.USD","LU1989772840.SGD","IE00BJT1NW94.SGD","LU1989764748.USD","LU2362541273.HKD","LU2362541513.USD","LU0114720955.EUR","LU0251132253.USD","LU1791710582.SGD","LU2087625088.SGD","IE00B2B36J28.USD","BK4585","LU1057294990.SGD","LU1366192091.USD","LU0048584097.USD","BK1100","LU2265009873.SGD","LU1983299246.USD","BK4082","LU0122379950.USD","LU2362540622.SGD","BK1574","LU2506952097.USD","LU0238689110.USD","LU0225283273.USD","LU2506951958.HKD","IE00BJJMRZ35.SGD","LU2242649171.HKD","LU1291159041.SGD","LU2244417387.USD","LU0353189680.USD","LU1153585028.USD","LU0882574055.USD","LU1791710400.SGD","LU2324357040.USD","LU0345769631.USD","LU1989772923.USD","LU2491050154.USD","BK1587","LU0823417737.USD","LU2112291526.USD","IE0002141913.USD","06669","LU1804176565.USD","LU2506952170.USD","LU1989771016.USD","LU1023059063.AUD","BK4581","LU2491050071.SGD"],"gpt_icon":0},{"id":"2540030773","title":"Acotec Scientific - Approval for Vertebral Artery Paclitaxel-Coated- Balloon Dilatation Catheter Acoart Verbena by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2540030773","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540030773?lang=en_us&edition=fundamental","pubTime":"2025-06-04 16:40","pubTimestamp":1749026441,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S706F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","06669","BK1100","BK1587"],"gpt_icon":0},{"id":"2540088442","title":"Ascletis Pharma Announces Successful Phase III Trial of Denifanstat, a Groundbreaking Oral FASN Inhibitor for Acne Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540088442","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540088442?lang=en_us&edition=fundamental","pubTime":"2025-06-04 07:15","pubTimestamp":1748992517,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has announced that its Phase III clinical trial for denifanstat , a first-in-class, once-daily oral fatty acid synthase  inhibitor, has met all primary, key secondary, and secondary endpoints for the treatment of moderate to severe acne vulgaris. The randomized, double-blind, placebo-controlled, multicenter trial conducted in China involved 480 patients. Denifanstat demonstrated a statistically significant improvement in treatment outcomes, with a 33.2% treatment success rate and reductions in total, inflammatory, and non-inflammatory lesion counts by 57.4%, 63.5%, and 51.9% respectively, compared to baseline. The trial results indicate that denifanstat was more effective than several FDA-approved acne treatments in placebo-adjusted percent treatment success. The drug maintained a favorable safety and tolerability profile throughout the study. Ascletis plans to submit the treatment for approval by the China National Medical Products Administration .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL63QMGf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1515","01672"],"gpt_icon":0},{"id":"2540088448","title":"Ascletis Announces Phase Iii Trial of Denifanstat (Asc40), a First-in-Class, Once-Daily Oral Fasn Inhibitor for Acne, Meets All Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2540088448","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540088448?lang=en_us&edition=fundamental","pubTime":"2025-06-04 07:15","pubTimestamp":1748992502,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA3LVHCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","BK1574","01672"],"gpt_icon":0},{"id":"2540088939","title":"Ascletis Pharma Inc -  Announces Phase Iii Trial of Denifanstat Meets All Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2540088939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540088939?lang=en_us&edition=fundamental","pubTime":"2025-06-04 07:00","pubTimestamp":1748991657,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60FU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1574","BK1515","BK1161"],"gpt_icon":0},{"id":"2540710707","title":"HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX Announcing Repurchase of 100,000 Shares at HKD 9.0667 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2540710707","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540710707?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:49","pubTimestamp":1748954942,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. has filed a next day disclosure return with the Hong Kong Stock Exchange, revealing that the company repurchased 100,000 shares to hold as treasury shares. The aggregate price paid for the repurchase was HKD 906,670, resulting in a price of HKD 9.0667 per share. The disclosure is pursuant to the company's share repurchase mandate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL60RH8b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1583","BK1161"],"gpt_icon":0},{"id":"2540969779","title":"Brii Biosciences Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540969779","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540969779?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:00","pubTimestamp":1748952047,"startTime":"0","endTime":"0","summary":"Brii Biosciences Ltd. held its annual general meeting on June 3, 2025. During the meeting, several proposals were voted on. The proposal to adopt the audited consolidated financial statements for the year ended December 31, 2024, was approved. The re-election of Dr. Ankang Li as an executive Director was also approved. Additionally, Mr. Gregg Huber Alton and Mr. Yiu Wa Alec Tsui were re-elected as independent non-executive Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL5qVDBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1587","02137"],"gpt_icon":0},{"id":"2540779388","title":"JW Cayman Therapeutics Co. Ltd. Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540779388","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540779388?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:50","pubTimestamp":1748951410,"startTime":"0","endTime":"0","summary":"JW Cayman Therapeutics Co. Ltd. held an extraordinary general meeting on June 3, 2025. During the meeting, a proposal to approve, ratify, and confirm the License Agreement and its execution, along with the implementation of the transactions contemplated under the agreement, was put forward. This proposal was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL7Wd6pM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1574","02126"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":84,"code":"91000000","status":"200"}]}}